We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.58B
AUM Growth
+$403M
Cap. Flow
+$220M
Cap. Flow %
13.93%
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.7M
3
PACB icon
Pacific Biosciences
PACB
+$11M
4
MDT icon
Medtronic
MDT
+$8.74M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.4M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.7M
2
BHC icon
Bausch Health
BHC
+$3.02M
3
AMGN icon
Amgen
AMGN
+$2.16M
4
GILD icon
Gilead Sciences
GILD
+$1.72M
5
KTWO
K2M Group Holdings, Inc
KTWO
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 93.18%
2 Industrials 1.09%
3 Technology 0.34%
4 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAH
26
DELISTED
PRA Health Sciences, Inc.
PRAH
$18.3M 1.16%
166,400
+37,000
+29% +$3.85M
WMGI
27
DELISTED
Wright Medical Group Inc
WMGI
$18.1M 1.15%
622,692
+52,391
+9% +$1.41M
HRC
28
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$17.5M 1.11%
185,689
+6,000
+3% +$563K
ESPR
29
DELISTED
Esperion Therapeutics
ESPR
$17.4M 1.1%
391,852
+78,332
+25% +$3.6M
WBA
30
DELISTED
Walgreens Boots Alliance
WBA
$16.5M 1.05%
226,018
– –
LH icon
31
Labcorp
LH
$23.2B
$16.3M 1.04%
109,463
+21,884
+25% +$3.33M
IONS icon
32
Ionis Pharmaceuticals
IONS
$8.99B
$16M 1.02%
310,536
-12,050
-4% -$566K
MGNX icon
33
MacroGenics
MGNX
$285M
$15.5M 0.99%
724,302
+127,389
+21% +$2.72M
KTWO
34
DELISTED
K2M Group Holdings, Inc
KTWO
$15.1M 0.96%
552,054
-60,887
-10% -$1.43M
ALDR
35
DELISTED
Alder Biopharmaceuticals
ALDR
$15.1M 0.96%
905,254
+146,290
+19% +$2.64M
ABMD
36
DELISTED
Abiomed Inc
ABMD
$14.9M 0.95%
33,135
+6,054
+22% +$2.39M
HOLX
37
DELISTED
Hologic
HOLX
$14.8M 0.94%
361,894
– –
AKCA
38
DELISTED
Akcea Therapeutics Inc
AKCA
$14.7M 0.93%
418,496
+39,195
+10% +$1.19M
LIVN icon
39
LivaNova
LIVN
$4.43B
$14.4M 0.92%
116,443
+6,519
+6% +$769K
PACB icon
40
Pacific Biosciences
PACB
$447M
$13.9M 0.88%
+2,575,000
New +$11M
BIIB icon
41
Biogen
BIIB
$30.4B
$13.9M 0.88%
39,245
-100
-0.3% -$34.4K
FIT
42
DELISTED
Fitbit, Inc. Class A common stock
FIT
$13.4M 0.85%
2,513,900
+456,000
+22% +$2.73M
HCM icon
43
HUTCHMED
HCM
$1.86B
$12.9M 0.82%
400,029
+67,493
+20% +$2.06M
ZBH icon
44
Zimmer Biomet
ZBH
$17.6B
$12.1M 0.77%
94,867
+21,324
+29% +$2.54M
SHPG
45
DELISTED
Shire pic
SHPG
$11.6M 0.74%
64,185
-1,107
-2% -$192K
INSM icon
46
Insmed
INSM
$23.5B
$11.5M 0.73%
566,301
+142,250
+34% +$3.21M
RMD icon
47
ResMed
RMD
$28.9B
$10.7M 0.68%
93,192
+10,992
+13% +$1.2M
GILD icon
48
Gilead Sciences
GILD
$167B
$10.6M 0.67%
137,500
-22,800
-14% -$1.72M
REGN icon
49
Regeneron Pharmaceuticals
REGN
$70.9B
$10.3M 0.65%
25,480
+8,220
+48% +$3.13M
DXCM icon
50
DexCom
DXCM
$29.6B
$10.2M 0.65%
286,588
-797,000
-74% -$24.7M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2018 Portfolio in Review

As of Q3 2018, Bellevue Group held 149 positions worth $1.58B, up 34% from $1.17B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $220M of net new capital in Q3 2018, opening 11 new positions and adding to 79 existing holdings. Its largest new stake was Pacific Biosciences: 2,575,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $24.7M trimmed.

  • Bellevue Group's largest Q3 2018 buy was Pacific Biosciences: 2,575,000 shares worth $13.9M.
  • Bellevue Group added most to Abbott in Q3 2018, an estimated $13M increase.
  • Bellevue Group's biggest Q3 2018 reduction was DexCom, cutting an estimated $24.7M.
  • Bellevue Group fully exited Bausch Health in Q3 2018, selling an estimated $3.02M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.58B portfolio in Q3 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q3 2018.
  • Bellevue Group's portfolio value rose 34% quarter-over-quarter to $1.58B.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.